Quarterly Financial Results for Period Ended June 30, 2026 - Contains consolidated financial statements including balance sheet as of June 30, 2026 and December 31, 2025, income statement data for Q2 2026 and six-month period ended June 30, 2026, with comparative periods from 2025 Product and Service Revenue Segmentation - Breaks down revenue between Product and Service segments for both…

Our analysis rates this filing NEUTRAL. IDEXX Laboratories presents a stable financial profile with a moderate concern level of 4.2/10. The company shows no material red flags or deteriorating business conditions. The single identified risk—supplier finance program obligations—is a routine working…

Concern level: ELEVATED (4.2/10). Key factors: Supplier finance program creates contingent payment obligations, though classified as standard accounts payable with no distress indicators; Overall risk score of 4.2/10 indicates balanced risk profile with no material deterioration.

Notable risk changes: Document is incomplete XBRL filing with primarily technical metadata - substantive business risk disclosures not accessible in provided excerpt; No material negative events, litigation, regulatory actions, or operational disruptions evident in available content; No executive changes, financial restatements, product recalls, or covenant violations disclosed.

The model predicts IDXX will underperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.